Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology
that has revolutionized the way we conceive immunotherapy. The impressive clinical results
of complete and prolonged response in refractory and relapsed diseases have shifted the
landscape of treatment for hematological malignancies, particularly those of lymphoid origin,
and opens up new possibilities for the treatment of solid neoplasms. However, the widening
use of cell therapy is hampered by the accessibility to viral vectors that are commonly used …